and hyperglycemia and increase effectiveness and safety of intensive glucose control. However, the overall accuracy and reliability of CGM and the effect of CGM on glucose control and prognosis in critically ill patients remain inconclusive. Therefore, we will conduct a systematic review to clarify the association between CGM and clinical outcome.
Methods and analysis:
We will search the database PubMed, EMASE, Cochrane Library databases from inception to October 2014. There will be no language restrictions. Studies comparing CGM with any other glucose monitoring methods in critically ill adult patients including trauma, surgical, medical, general intensive care unit (ICU) patients, and so on will be included. Both observational and randomized controlled studies will be included. Jadad criteria and Newcastle Ottawa Scale will be used to assess the quality of included studies. The primary outcomes are mortality and the pearson correlation coefficient between CGM and other glucose monitoring methods. The secondary outcomes includes the incidence of severe hypoglycemia, the incidence of glucose levels above 9.0 mmol/L, mean glucose levels, percentage of time within
INTRODUCTION
In intensive care unit, up to 90% of critically ill patients may experience hyperglycemia which has F o r p e e r r e v i e w o n l y been reported to be associated with adverse outcomes, including morbidity and mortality.
1, 2 Van den Berghe et al reported that intensive insulin therapy could significantly decrease the risk of morbidity and mortality, 3 however, this benefit was not observed by several subsequent studies and a large meta-analysis including 26 randomized trials enrolling 13567 patients indicated that intensive insulin therapy not only had no effect on survival in critically ill patients but also resulted in a sixfold increase of severe hypoglycemia. [4] [5] [6] As a result, this two multicenter studies were stopped prematurely because of high incidence of hypoglycemia. 4, 5 In addition to hyperglycemia and hypoglycemia, high glucose variability has also been shown to be related with adverse outcomes. [6] [7] [8] [9] [10] [11] Glucose regulation is a challenge in intensive care unit and requires frequent monitoring of glucose. However, the conventional glucose regulation regimens often increase the workload for intensive care nurse, and increase the number of blood samples and accompanying blood loss. What is more serious is that the insulin induced severe hypoglycemia may be unnoticed between the two measurements. 12 To optimize glucose control, it is necessary to monitor glucose levels in real time. In the management of diabetic patients, subcutaneous (continuous glucose monitoring) CGM has been extensively evaluated. [13] [14] [15] The accuracy and reliability of this CGM sensor have been evaluated in critically ill patients in several small studies in recent years. [16] [17] [18] [19] However, up to now, the overall accuracy and reliability of CGM has not been well defined and conflicting results exist among studies. For instance, the pearson correlation coefficient ranged from 0.69 to 0.92 as reported by different studies. 16, 17 And whether the subcutaneous real-time CGM improves glucose control and prognosis, and reduces the risk of hypoglycemia remain inconclusive. We describe here the protocol of a systematic review and meta-analysis to investigate the overall accuracy and 
METHODS
The present systematic review and meta-analysis will be reported according to the recommendations from the preferred reporting items for systematic reviews and meta-analyses (PRISMA, www.prisma-statement.org/) and the meta-analysis of observational studies in epidemiology (MOOSE).
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Search methods for identifying studies Electronic searches
We will systematically search the database PubMed, EMASE, Cochrane Library databases from inception to October 2014. We also will screen the reference lists of relevant trials and reviews for additional articles. In addition, we will search the following databases for unpublished or ongoing studies: http://www.controlled-trials.com and http://clinicaltrials.gov and review of abstracts from selected scientific proceedings (Society of Critical Care Medicine and European Society of Intensive Care Medicine). There will be no language restrictions.
Search terms/search strategy
The keywords and medical subject headings related to CGM (continuous glucose monitoring, severely ill and emergency) will be used alone or in combination. The search strategy has been developed for PubMed and similar search strategy will be adapted for the other databases.
Inclusion criteria of studies Participants
Studies including adult (≥16 years old) critically patients (general ICU patients, medical ICU patients, surgical ICU patients, trauma ICU patients, and so on) will be eligible in our meta-analysis.
Intervention group and control group
Glucose regulation in the intervention group is performed by use of a subcutaneous CGM system.
In the control group, blood glucose levels are regulated by conventional methods (point-of-care devices, arterial blood gas analysis, and central laboratory).
Study endpoints
The primary outcomes are mortality with the longest follow-up period and the pearson correlation coefficient between CGM and other glucose monitoring methods. The secondary outcomes includes the incidence of severe hypoglycemia (< 2.2 mmol/L or 40 mg/dL), 21 
Selection of studies
Two authors (Libing Jiang and Shouyin Jiang) will independently screen all the titles and abstracts of literature search for eligibility. After title and abstract review, potential articles will be further independently reviewed in full texts by the same two authors (Libing Jiang and Shouyin Jiang) to determine the eligibility according to the predefined inclusion and exclusion criteria. Discrepancy will be resolved by consensus or discussion with another reviewer (Yuefeng Ma or Mao Zhang).
Data extraction
Data extraction will be completed independently by two authors (Libing Jiang and XiaFeng) using a predefined data extraction sheet. Any discrepancy will be resolved by consensus and discussion with anther reviewer (Yuefeng Ma or Mao Zhang). The following relevant data will be collected from original articles: the name of the first author, publication year, country of origin, types of settings (general ICU patients, surgical ICU patients, trauma ICU patients, and so on), patients characteristics (gender, age, number, inclusion and exclusion criteria), characteristics of interventions, characteristics of control methods (venous blood glucose, capillary blood glucose or artery blood glucose), target blood glucose range, mortality, pearson correlation coefficient between the intervention and control group and according 95% confidence interval (CI), incidence of severe hypoglycemia (< 2.2 mmol/L or 40 mg/dL) in the study and control arms, the incidence of glucose levels above 9.0 mmol/L in the study and control arms, mean glucose levels in the study and control arms, percentage of time within target range, duration of mechanical ventilation, The methodological quality of RCTs will be evaluated by using the Jadad criteria ( Table 2 ). The Jadad scale determines the quality of an RCT from three aspects: 1) randomization; 2) Double-blinding; 3) explanation of withdrawals or loss to follow-up (http://www.anzjsurg. Com / view/0/JadadScore.html). Studies will be considered to be of low quality if the Jadad score is less than 2and high quality if the score is more than 3.
Newcastle-Ottawa Scale will be used to assess the methodological quality of included observational studies (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). The quality of a study will be judged by the selection of the study groups, the comparability of the groups, and the ascertainment of the outcome. The selection of the study groups will be evaluated from four items: representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure to implants and demonstration that outcome of interest is not present at start of study. The comparability of the groups will be evaluated from one item: study controls for confounders. The ascertainment of the outcome will be evaluated from three items: assessment of outcome, duration of follow up and completeness of follow up. A study can be awarded a maximum of one star for each numbered item within selection and outcome categories. A maximum of two stars can be given for comparability.
Statistical analysis and data synthesis
Stata 12.0 (SERIAL NO.40120519635) will be used to calculate pooled odd ratios (ORs) and 95%
CIs for dichotomous variables (mortality, the incidence of severe hypoglycemia, the incidence of glucose levels above 9.0 mmol/L and percentage of time within target range) and pooled weighted mean differences (WMDs) and 95% CIs for continuous variables (mean glucose levels, duration of mechanical ventilation and the length of ICU and hospital stay and control group and according 95% confidence interval (CI) will be combined using the method of "generic inverse variance" (http://www.cochrane.org/handbook). The data required for the generic inverse variance method are an estimate for the pearson correlation coefficient and its standard error (SE) for each of the studies. Each study is given a weight which is equal to the inverse of the variance of the effect estimate (i.e. one divided by the standard error squared). Then, we need to enter the napierian logarithm (ln) of the effect size and the standard error of the ln (pearson correlation coefficient). If these two values are entered as the effect estimate and standard error, from them STATA 12.0 will calculate the effect size and 95%CI (this is not on the log scale).
In our study, we will use the 95% CI of pearson correlation coefficient to work backwards and calculated the SE of the ln (pearson correlation coefficient).
Assessment of heterogeneity
Heterogeneity will be assessed using Cochran's Q-statistic and I 2 statistic, P<0.1 or I 2 >50%
indicates the presence of significant heterogeneity. 22, 23 I 2 will be calculated according to the equation I 2 =100% × (Q−df)/Q, where Q is the Cochran heterogeneity statistic.
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Subgroup analysis
In order to further evaluate the effect of CGM on critically ill patients and explore heterogeneity among component studies, the following subgroup analyses will be performed according to the number of studies available. Firstly, subgroup analysis will be performed based on the types of patients (general ICU patients, surgical ICU patients, trauma ICU patients and so on); secondly, subgroup analysis will be performed based on methods of blood glucose monitoring in the control 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y group (venous blood glucose, capillary blood glucose or artery blood glucose); finally, we will perform subgroup analysis according to the types of study designs (RCT or observational study).
Sensitivity analysis
Firstly, Sensitivity analysis will be performed by excluding trials at high risk of bias; Secondly, a leave-one-out sensitivity analysis will be performed by iteratively removing 1 study at a time to confirm the robustness of our results; Thirdly, sensitivity analysis will be performed by examining the effect of CGM on mortality by using RR as a measure of treatment effect and RD as a measure of treatment effect.
Publication bias
Publication bias in meta-analysis is commonly explored using funnel plots. Symmetrical appearance of the plot indicates that there is non-significant publication bias. However, asymmetry in the appearance of a funnel plot can be explained by many factors including publication bias and different study quality. 24 Therefore, the contour enhanced funnel plot will be applied to aid in interpreting the funnel plot. If studies are missing in areas of low statistical significance, the asymmetry may be due to publication bias. If studies are missing in areas of high statistical significance, the asymmetry may be due to other factors. 24 In addition, Egger's test will be used to quantitatively detect publication bias. Egger's method regresses the standard normal deviate on precision. This regression line must be weighed by the inverse of variance. If the regression line originates in the Y-axis zero indicates there isn't significant publication bias. And much further away from zero, further evidence of publication bias.
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DISCUSSION
Stress induced hyperglycemia is common in ICU patients which has been reported is an [3] [4] [5] However, irrespective of the selected blood glucose target range, in all RCTs, the predefined target range was not reached due to the increased rate of severe hypoglycemia. 4, 5, 7 A large meta-analysis even reported that intensive insulin therapy resulted in a sixfold increase of severe hypoglycemia. 6 Based on the above analysis, we have reason to believe that the real benefit of intensive glucose control may be masked by severe hypoglycemia. Therefore, real-time continuous glucose monitoring (CGM) may be more appropriate than conventional glucose monitoring in managing hyperglycemia in critically ill patients. In the management of diabetic patients, subcutaneous CGM has been extensively evaluated. [13] [14] [15] The accuracy and reliability of this CGM sensor have been evaluated in critically ill patients in recent years. [16] [17] [18] [19] However, up to now, the overall accuracy and reliability of CGM has not been well defined and conflicting results exist among studies. For instance, the pearson correlation coefficient between CGM and conventional glucose control methods ranged from 0.69 to 0.92 as reported by different studies. 16, 17 Although it has been reported that CGM can significantly decrease the rate of severe hypoglycemia, the workload of intensive care nurses and cost, 12, 28 whether CGM improves glucose control and prognosis remain inconclusive. We describe here the protocol of a systematic review and meta-analysis to investigate the overall accuracy and reliability of subcutaneous real-time CGM as compared with different reference methods and whether subcutaneous real-time CGM is beneficial in critically ill patients. The above authors all are members of China Emergency and Critical Care Evidence-based Medicine Group (CECCEBMG).
ABSTRACT
Introduction:
Stress induced hyperglycemia which has been shown to be associated with unfavorable prognosis is common among critically ill patients. Additionally, it has been reported that hypoglycemia, and high glucose variabilities are also associated with adverse outcomes. Thus continuous glucose monitoring (CGM) may be the optimal method to detect severe hypoglycemia, hyperglycemia and decrease glucose excursion. However, the overall accuracy and reliability of CGM system and effects of CGM system on glucose control and prognosis in critically ill patients remain inconclusive. Therefore, we will conduct a systematic review and meta-analysis to clarify the association between CGM system and clinical outcome.
Methods and analysis:
We will search the PubMed, EMBASE, and Cochrane Library from inception to October 2014. Studies comparing CGM system with any other glucose monitoring methods in critically ill patients will be eligible for our meta-analysis. The primary endpoints include the incidence of hypoglycemia and hyperglycemia, mean glucose level, and percentage of time within target range. The second endpoints include ICU mortality, hospital mortality, duration of mechanical ventilation, the length of ICU and hospital stay and the Pearson correlation coefficient and the results of error grid analysis. In addition, we will furthermore record all complications (e.g. acquired infections) in two groups and local adverse events in the intervention group (e.g. bleeding or infections).
Ethics and dissemination:
Ethical approval is not required given this is a protocol for a systematic review. The findings will be disseminated in a peer-reviewed journal and presented at a relevant conference.
Trial registration number: PROSPERO registration number: CRD42014013488. 
Strengths and limitations of this study
This review will be the first high-quality systematic review and meta-analysis to synthesise the current evidence about the application of continuous glucose monitoring in intensive care unit. And it will let more clinicians to be aware of the value of continuous glucose monitoring.
This review will be limited by the quality and heterogeneity of the primary studies, especially the inclusion of observational studies. 3 however, these benefits did not be observed by several subsequent studies as well as a large meta-analysis. In this meta-analysis, the authors indicated that intensive insulin therapy not only had no effect on survival rate in critically ill patients but also resulted in a six-fold increase of severe hypoglycemia. [4] [5] [6] As a result, two multicenter studies were stopped prematurely because of high incidence of hypoglycemia. 4, 5 Apart from hyperglycemia and hypoglycemia, the elevated glucose variability has also been shown to be related with adverse outcomes. [6] [7] [8] [9] [10] [11] Therefore, glucose regulation remains a challenge in intensive care unit. One of the factors which may lead to the high incidence of hyperglycemia and hypoglycemia and increased glucose fluctuation is that the glucose levels in critically ill patients cannot be measured continually. The conventional glucose monitoring regimens often require nurses to monitor blood glucose frequently and this not only increases the workload for the intensive care nurses, but also increases the number of blood samples and accompanying blood loss. What is more serious is that the insulin induced severe hypoglycemia may be unnoticed between two measurements. 12 To optimize glucose control, it is necessary to monitor glucose levels in real time. Subcutaneous (continuous glucose monitoring) CGM has been extensively evaluated in diabetic patients. [13] [14] [15] In critically ill patients, the accuracy and reliability of CGM sensors have been evaluated in several small studies in recent years, [16] [17] [18] [19] however, the Pearson correlation coefficients which were reported by different studies ranged from 0.69 to 0.92. 16, 17 Additionally, little is known about whether there is a discernable association between the application of CGM and satisfactory glycemic control and improved prognosis. We describe here the protocol of a systematic review and meta-analysis, in order to explore the overall accuracy and reliability of CGM as compared with other reference methods in critically patients and examine whether the use of CGM could decrease the incidence of hypoglycemia and hyperglycemia and improve the prognosis of critically ill patients. This systematic review has been registered with PROSPERO (the NIHR International Prospective Register of Systematic Reviews, http://www.crd.york.ac.uk/PROSPE RO/) under registration number CRD42014013488. 
METHODS
The present systematic review and meta-analysis will be reported according to the recommendations from the preferred reporting items for systematic reviews and meta-analyses (PRISMA,www.prisma-statement.org/) (Supplementary file 2) .
Search methods for identifying studies Electronic searches
We will systematically search the PubMed, EMBASE, and Cochrane Library from inception to October 2014. We will also screen the reference lists of relevant studies and reviews for additional
articles. In addition, we will search the following websites for unpublished or ongoing studies:
http://www.controlled-trials.com and http://clinicaltrials.gov and review of abstracts from selected scientific proceedings (Society of Critical Care Medicine and European Society of Intensive Care Medicine). There will be no language restrictions. If there are non-Chinese or non-English studies,
we will invite experts to translate these documents into Chinese or English.
Search terms/search strategy
The keywords and medical subject headings related to CGM (continuous glucose monitoring, real-time glucose monitoring, real-time continuous glucose monitoring, subcutaneous continuous glucose monitoring, and continuous measurement of glucose) and critically ill patients (intensive care, ICU, critically ill, intensive care unit, critical care, critical illness, critical care nursing, severely ill and emergency) will be used alone or in combination to retrieve relevant articles. The search strategy has been developed for PubMed (Supplementary File1), and similar search strategy will be adapted for the other databases.
Inclusion criteria of studies Participants
Studies, including critically patients (general ICU patients, medical ICU patients, surgical ICU patients, trauma ICU patients, and so on) will be eligible for our meta-analysis.
Intervention group and control group
In the control group, blood-glucose levels are regulated by conventional methods (point-of-care devices, arterial blood gas analysis, or central laboratory). In some studies, patients in the control group may also receive the CGM system; however, these data must be blinded to nurses and clinicians and not used for glucose regulation and these studies will be also eligible for our meta-analysis. Whether in the intervention group or control group, calibrations of the CGM system are performed according to manufacturer instructions, and no restriction will be placed on the frequency of calibrations.
Study endpoints
The primary endpoints include the incidence of hypoglycemia and severe hypoglycemia 20 , the incidence of hyperglycemia, mean glucose level, and percentage of time within target range. For hypoglycemia, severe hypoglycemia, hyperglycemia and normal range of glucose target, we will use definitions as defined in the included studies.
The second endpoints included ICU mortality, hospital mortality, duration of mechanical ventilation, and the length of ICU and hospital stay. In order to assess the accuracy of CGM system, we will as well as extract the Pearson correlation coefficient and the results of error grid analysis between CGM system and other glucose monitoring methods. In the error grid analysis, we will extract the percentage of data points, which fall within in Zone A, B, C, D, E. In addition,
we will furthermore record all complications (e.g. acquired infections) in two groups and local adverse events in the intervention group (e.g. bleeding or infections).
Study design
Both prospective and retrospective observational cohort studies and randomized controlled trials (RCTs) will be eligible for the present systematic review and meta-analysis.
Data collection and analysis
Selection of studies
Three reviewers (Weidong Zhu, Libing Jiang and Shouyin Jiang) will independently examine the titles and/or abstracts and eliminate irrelevant studies. All potential eligible studies will be read in of error grid analysis, the incidence of hypoglycemia and hyperglycemia, mean glucose levels, percentage of time within target range, duration of mechanical ventilation, duration of follow-up, the length of ICU and hospital stay, all complications in the two groups, and adverse events in the intervention group. If necessary (unclear data, missing data and extractable data) we will attempt to contact the corresponding authors of the included studies for missing data and for clarification.,
Data extraction
Assessment of the quality of included studies
The methodological quality of RCTs will be evaluated by using the Jadad criteria ( Table 1 ). The Jadad scale determines the quality of an RCT from three domains: 1) randomization; 2) Double-blinding; 3) explanation of withdrawals or loss to follow up (http://www.anzjsurg.Com / view/0/JadadScore.html). Studies will be considered to be of low quality if the Jadad score is less than 2 and high quality if the score is more than 3. Newcastle-Ottawa Scale will be used to assess the methodological quality of included observational studies (http://www.ohri.ca/programs/ clinical_epidemiology/oxford.asp). The quality of a study will be judged by the selection of the study groups, the comparability of the groups, and the ascertainment of the outcome. The selection of the study groups will be evaluated from four items: representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure to implants and demonstration that outcome of interest is not present at the start of study. The comparability of the groups will be evaluated from one item: study controls for confounders. The ascertainment of the outcome will be evaluated from three items: assessment of outcome, duration of follow up and completeness of follow up. A study can be awarded a maximum of one star for each numbered item within selection and outcome categories. A maximum of two stars can be given for comparability. All the above processes are completed independently by two reviewers and inter-rater agreement will be 
Dealing with missing data
If there are any missing or insufficient data from included studies, we will contact the first or corresponding authors of the studies by telephone or email to obtain more information. If we are unable to obtain the missing data, the methods which were reported by Ebrahim et al 21 and Akl et al 22 will be used to perform complete case analysis. And a sensitivity analysis will be conducted.
Statistical analysis and data synthesis
Stata 12.0 (SERIAL NO. 40120519635) will be used to calculate pooled odd ratios (ORs) and 95%
CIs for dichotomous variables and pooled weighted mean differences (WMDs) and 95% CIs for continuous variables. Fixed-effect model and random-effect model will be used to pool effect size as appropriate according to the results of heterogeneity tests (http://www.cochrane.org/handbook).
If the included studies exist heterogeneity, the random-effect model will be used; otherwise, the fixed-effect model will be used. The Pearson correlation coefficient between the intervention and control group and according 95% confidence interval (CI) will be combined using the method of 
Assessment of heterogeneity
indicates the presence of significant heterogeneity. 
Meta-regression and subgroup analysis
We will perform meta-regression to test the significance of each pre-defined covariate, including year of publication, age (i.e. pediatric or adult), type and generation of CGM device, type of 
Sensitivity analysis
Firstly, Sensitivity analysis will be performed by excluding trials at high risk of bias; Secondly, a leave-one-out sensitivity analysis will be performed by iteratively removing one study at a time to confirm the robustness of our results.
Publication bias
Symmetrical appearance of the plot indicates that there is non-significant publication bias.
However, asymmetry in the appearance of a funnel plot can be explained by many factors, including publication bias and different study quality. 25 Therefore, the contour enhanced funnel plot will be applied to aid in interpreting the funnel plot. If studies are missing in areas of low statistical significance, the asymmetry may be due to publication bias. If studies are missing in areas of high statistical significance, the asymmetry may be due to other factors. 25 In addition, Egger's test will be used to quantitatively detect publication bias. Egger's method regresses the standard normal deviate on precision. This regression line must be weighed by the inverse of variance. If the regression line originates in the Y-axis zero indicates there isn't significant publication bias, and much further away from zero, further evidence of publication bias.
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DISCUSSION
Stress induced hyperglycemia which is common in ICU has been reported is an independent risk factor of adverse outcomes. 27, 28 Up to recently, management of hyperglycemia in critically ill patients has been a hot topic of discussion. Especially, weather tight glycemic control is beneficial or harmful for critically ill patients? The benefit of intensive insulin control which was reported by
Van den Berghe et al could not be observed in subsequent RCTs. [3] [4] [5] However, irrespective of the selected blood-glucose target range, in all RCTs, the predefined target range was not reached due to the increased rate of severe hypoglycemia. 4, 5, 7 A large meta-analysis even reported that intensive insulin therapy was associated with a six-fold increase of severe hypoglycemia. 6 Based on the above analysis, we have reason to speculate that the real benefit of intensive glucose control may be masked by the incidence of severe hypoglycemia. Additionally, substantial glucose fluctuation has also been shown to be related with unfavorable outcomes. Whereas, it is difficult to achieve a further decrease of the glucose excursions through current glucose monitoring methods.
Therefore, real-time continuous glucose monitoring (CGM) may be more appropriate in managing hyperglycemia in critically ill patients. Subcutaneous CGM has been extensively evaluated in the management of diabetic patients. [13] [14] [15] Although the CGM system has been used in critically ill patients in recent years, and has been reported to be associated with a decrease risk of severe hypoglycemia, 12, 29 the overall accuracy and reliability of the CGM system have not been well-defined. [16] [17] [18] [19] For instance, the Pearson correlation coefficient between the CGM system and conventional glucose monitoring methods ranged from 0.69 to 0.92, as reported by different studies. 16, 17 Moreover, we still do not know whether the CGM system reduces the workload of nurses and the medical cost along with improves the effects of glucose control and the prognosis of critically ill patients. Therefore, a high quality systematic review and meta-analysis is need and figure 1 show an overview of our study. Our review will be limited by the quality and heterogeneity of the primary studies, including noted between-study variability in the enrolled patient population; different glucose regulation protocol, different type and generation of CGM device, different frequency of calibration, and different definition of hypoglycemia, hyperglycemia, and target glucose range. Additionally, observational studies, especially retrospective cohort studies will be included in our meta-analysis; this may increase the risk of potential selection and information bias, and the imbalanced baseline variables in observational studies will further limit the generalization of our results. who will also independently screen the potential studies, extract data from the included studies, assess the risk of bias and complete the data synthesis. MZ and YFM will arbitrate in cases of disagreement and ensure the absence of errors. All authors approved the publication of the protocol. The above authors all are members of China Emergency and Critical Care
Evidence-based Medicine Group (CECCEBMG).
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Data sharing statement:
The findings of this systematic review will be disseminated via peer-reviewed publications and conference presentations. ABSTRACT Introduction: Stress induced hyperglycemia which has been shown to be associated with unfavorable prognosis is common among critically ill patients. Additionally, it has been reported that hypoglycemia, and high glucose variabilities are also associated with adverse outcomes. Thus continuous glucose monitoring (CGM) may be the optimal method to detect severe hypoglycemia, hyperglycemia and decrease glucose excursion. However, the overall accuracy and reliability of CGM system and effects of CGM system on glucose control and prognosis in critically ill patients remain inconclusive. Therefore, we will conduct a systematic review and meta-analysis to clarify the association between CGM system and clinical outcome.
Methods and analysis:
Ethics and dissemination:
Trial registration number: PROSPERO registration number: CRD42014013488.
Strengths and limitations of this study
This review will be the first high-quality systematic review and meta-analysis to synthesise the current evidence about the application of continuous glucose monitoring in intensive care unit. And it will let more clinicians to be aware of the value of continuous glucose 3 however, these benefits did not be observed by several subsequent studies as well as a large meta-analysis. In this meta-analysis, the authors indicated that intensive insulin therapy not only had no effect on survival rate in critically ill patients but also resulted in a six-fold increase of severe hypoglycemia. [4] [5] [6] As a result, two multicenter studies were stopped prematurely because of high incidence of hypoglycemia. 4, 5 Apart from hyperglycemia and hypoglycemia, the elevated glucose variability has also been shown to be related with adverse outcomes. [6] [7] [8] [9] [10] [11] Therefore, glucose regulation remains a challenge in intensive care unit. One of the factors which may lead to the high incidence of hyperglycemia and hypoglycemia and increased glucose fluctuation is that the glucose levels in critically ill patients cannot be measured continually. The conventional glucose monitoring regimens often require nurses to monitor blood glucose frequently and this not only increases the workload for the intensive care nurses, but also increases the number of blood samples and accompanying blood loss. What is more serious is that the insulin induced severe hypoglycemia may be unnoticed between two measurements.
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To optimize glucose control, it is necessary to monitor glucose levels in real time. Subcutaneous (continuous glucose monitoring) CGM has been extensively evaluated in diabetic patients. [13] [14] [15] In critically ill patients, the accuracy and reliability of CGM sensors have been evaluated in several small studies in recent years, [16] [17] [18] [19] however, the Pearson correlation coefficients which were reported by different studies ranged from 0.69 to 0.92. 16, 17 Additionally, little is known about whether there is a discernable association between the application of CGM and satisfactory glycemic control and improved prognosis. We describe here the protocol of a systematic review and meta-analysis, in order to explore the overall accuracy and reliability of CGM as compared with other reference methods in critically patients and examine whether the use of CGM could 
METHODS
Search methods for identifying studies Electronic searches
http://www.controlled-trials.com and http://clinicaltrials.gov and review of abstracts from selected scientific proceedings (Society of Critical Care Medicine and European Society of Intensive Care Medicine). There will be no language restrictions. If there are non-Chinese or non-English studies, we will invite experts to translate these documents into Chinese or English.
Search terms/search strategy
Inclusion criteria of studies Participants
Intervention group and control group
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Study endpoints
Study design
Data collection and analysis
Selection of studies
Three reviewers (Weidong Zhu, Libing Jiang and Shouyin Jiang) will independently examine the titles and/or abstracts and eliminate irrelevant studies. All potential eligible studies will be read in full text and their suitability for inclusion will be determined in terms of PICO (Participant, 
Data extraction
Two reviewers (Weidong Zhu and Libing Jiang) will abstract data from the retrieved trials independently using a predefined data extraction sheet. Any discrepancy will be managed by consensus. The following variables will be recorded for each study: the name of the first author, publication year, country of origin, type of setting (general ICU patients, surgical ICU patients, trauma ICU patients, and so on), patients' characteristics (gender, age, number, inclusion and exclusion criteria), characteristics of interventions, characteristics of control methods (venous blood glucose, capillary blood glucose or artery blood glucose), target blood glucose range, mortality, Pearson correlation coefficient between CGM system and other methods and the results of error grid analysis, the incidence of hypoglycemia and hyperglycemia, mean glucose levels, percentage of time within target range, duration of mechanical ventilation, duration of follow-up, the length of ICU and hospital stay, all complications in the two groups, and adverse events in the intervention group. If necessary (unclear data, missing data and extractable data) we will attempt to contact the corresponding authors of the included studies for missing data and for clarification.,
Assessment of the quality of included studies
The methodological quality of RCTs will be evaluated by using the Jadad criteria ( Table 1 ). The Jadad scale determines the quality of an RCT from three domains: 1) randomization; 2) Double-blinding; 3) explanation of withdrawals or loss to follow up (http://www.anzjsurg.Com / view/0/JadadScore.html). Studies will be considered to be of low quality if the Jadad score is less than 2 and high quality if the score is more than 3. Newcastle-Ottawa Scale will be used to assess the methodological quality of included observational studies (http://www.ohri.ca/programs/ clinical_epidemiology/oxford.asp). The quality of a study will be judged by the selection of the study groups, the comparability of the groups, and the ascertainment of the outcome. The selection of the study groups will be evaluated from four items: representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure to implants and demonstration that outcome of interest is not present at the start of study. The comparability of the groups will be evaluated from one item: study controls for confounders. The ascertainment of the outcome will be evaluated from three items: assessment of outcome, duration of follow up and completeness of follow up. A study can be awarded a maximum of one star for each numbered item within selection and outcome categories. A maximum of two stars can be given for comparability. All the above processes are completed independently by two reviewers and inter-rater agreement will be assessed using Kappa statistic.
Dealing with missing data
Statistical analysis and data synthesis
If the included studies exist heterogeneity, the random-effect model will be used; otherwise, the fixed-effect model will be used. The Pearson correlation coefficient between the intervention and control group and according 95% confidence interval (CI) will be combined using the method of "generic inverse variance" (http://www.cochrane.org/handbook). The data required for the generic inverse variance method are an estimate for the Pearson correlation coefficient and its standard error (SE) for each of the studies. Each study is given a weight which is equal to the inverse of the variance of the effect estimate (i.e. one divided by the standard error squared). Then, we need to enter the napierian logarithm (ln) of the effect size and the standard error of the ln (Pearson correlation coefficient). If these two values are entered as the effect estimate and standard error, from them STATA 12.0 will calculate the effect size and 95%CI (this is not on the log scale). In our study, we will use the 95% CI of Pearson correlation coefficient to work backwards and calculated the SE of the ln (Pearson correlation coefficient.).
Assessment of heterogeneity
indicates the presence of significant heterogeneity. 23 
Meta-regression and subgroup analysis
We will perform meta-regression to test the significance of each pre-defined covariate, including year of publication, age (i.e. pediatric or adult), type and generation of CGM device, type of patient (general ICU patients, surgical ICU patients, trauma ICU patients and so on), method of blood-glucose monitoring in the control group (venous blood glucose, capillary blood glucose or artery blood glucose), calibration frequency, and type of the study design (RCT or observational study). Additionally, we will perform subgroup analyses based on covariates which are statistically significance in the meta-regression.
Sensitivity analysis
Publication bias
26
DISCUSSION
Therefore, real-time continuous glucose monitoring (CGM) may be more appropriate in managing hyperglycemia in critically ill patients. Subcutaneous CGM has been extensively evaluated in the management of diabetic patients. [13] [14] [15] Although the CGM system has been used in critically ill patients in recent years, and has been reported to be associated with a decrease risk of severe hypoglycemia, 12, 29 the overall accuracy and reliability of the CGM system have not been well-defined. [16] [17] [18] [19] For instance, the Pearson correlation coefficient between the CGM system and conventional glucose monitoring methods ranged from 0.69 to 0.92, as reported by different studies. 16, 17 Moreover, we still do not know whether the CGM system reduces the workload of nurses and the medical cost along with improves the effects of glucose control and the prognosis of critically ill patients. Therefore, a high quality systematic review and meta-analysis is need and figure 1 show an overview of our study. Our review will be limited by the quality and heterogeneity of the primary studies, including noted between-study variability in the enrolled patient population; different glucose regulation protocol, different type and generation of CGM device, different frequency of calibration, and different definition of hypoglycemia, hyperglycemia, and target glucose range. Additionally, observational studies, especially retrospective cohort studies will be included in our meta-analysis; this may increase the risk of potential selection and information bias, and the imbalanced baseline variables in observational studies will further limit the generalization of our results.
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